Connecticut Magazine recognizes Yale Cancer Center and Smilow Cancer Hospital physicians as 'Best Doctors'
Connecticut Magazine has named 77 Yale Cancer Center and Smilow Cancer Hospital at Yale New Haven physicians and surgeons to its 2018 Best Doctors guide. Published in the magazine's April issue, the Best Doctors list consists of 779 Connecticut physicians from 78 medical specialties.
Meriano's Cannoli Truck: A Family's Sweet Mission
Heartened by the care their patriarch received from Yale-New Haven's Smilow Cancer Center, and specifically thoracic surgeon Dr. Daniel Boffa, the Merianos vowed to donate a percentage of sales from the truck to the hospital's Thoracic Oncology Program Fund.Source: CTNow.com
Concurrent Chemoradiation Treatment at High-Volume Facilities Improves Survival for Non-Small Cell Lung Cancer Patients
Patients treated with definitive concurrent chemotherapy and radiation therapy (CCRT) for stage III non-small cell lung cancer (NSCLC) have longer overall survival when treated by highly experienced facilities, whether or not they are academic or community cancer centers.Source: IASLC
For some lung cancer patients, surgery may yield better long-term results
Patients with early stage non-small cell lung cancer (NSCLC) who are otherwise healthy fare better over time if they undergo conventional surgery versus less-invasive radiosurgery to remove their cancer, according to a Yale study. The findings are scheduled to be presented at the 56th annual conference of the American Society for Radiation Oncology in San Francisco.
Dr. Herbst on the FDA Approval of Adjuvant Pembrolizumab in NSCLC
Roy S. Herbst, MD, PhD, ensign professor of medicine, medical oncology, professor, pharmacology, director, Center for Thoracic Cancers, Assistant Dean for Translational Research, Yale School of Medicine; deputy director, Yale Cancer Center; chief, Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses the significance of the FDA approval of adjuvant pembrolizumab (Keytruda) in patients with non–small cell lung cancer (NSCLC).Source: OncLive
Gap Discovered in Breast Cancer Radiotherapy Recommendations for Patients Aged 70 vs 69 Years
Age-based heuristics may lead to large differences in breast cancer treatment based on small differences in chronologic age, according to a new study published by Talcott et al in the International Journal of Radiation Oncology, Biology, and Physics.Source: The ASCO Post
Yale’s Endocrine Neoplasia Program Is Flourishing
The Yale Multidisciplinary Endocrine Neoplasia Clinic has been treating benign and malignant diseases of the thyroid, parathyroid, adrenal, and pituitary glands since 2013. The program is a collaboration between the Department of Internal Medicine’s Section of Endocrinology & Metabolism and Yale Cancer Center and Smilow Cancer Hospital.
Doctors seeing success in HPV vaccine against cancers
(WTNH) – The only vaccine to prevent cancer has been on the market for a number of years, but doctors are now seeing the actual generation benefiting. It’s the HPV vaccine, which can prevent cervical cancer and it’s proving to be extremely effective. Doctor Elena Ratner, a gynecologic oncologist at Yale Cancer Center and Smilow Hospital says success is being seen as a result of Gardasil 9, the vaccine to prevent HPV, which is a sexually-transmitted disease that can lead to cancers.Source: WTNH
Yale expert familiar with procedure used on First Lady Jill Biden’s skin cancer
In light of First Lady Jill Biden's diagnosis and subsequent treatment for basal cell cancer, Yale dermatologic surgeons David Leffell, MD explains the symptoms of the condition and expands on the Moh's surgery technique used to remove the First Lady's cancer.Source: WTNH News8
Experts Study Implications of Genetic Markers in Prostate Cancer
In this video, Stacy Loeb, MD, MSc, and Veda N. Giri, MD, discuss the European Urology paper “Genetic Risk Prediction for Prostate Cancer: Implications for Early Detection and Prevention,” for which they served as coauthors. Giri is division chief of Clinical Cancer Genetics for Yale Cancer Center and Smilow Cancer and assistant director of Clinical Cancer Genetics for Yale Cancer Center, New Haven, Connecticut. Loeb is a professor in the departments of urology and population health at the NYU Grossman School of Medicine, New York City, New York.Source: Urology Times
HER2 Low Breast Cancer: New Clinical Entity or Testing Artifact
Should breast cancer patients with low but not negative tumor expression of HER2 be considered a distinct patient group that can be treated differently from patients with tumors that are HER2 negative or HER2 positive? That was the question posed during a session at the recent San Antonio Breast Cancer Symposium (SABCS) 2022.Source: Medscape
The VA Launches Largest-Ever Trial on Screening Methods for Liver Cancer
The largest clinical trial in history related to liver cancer screening is launching in 2023, funded by the Department of Veterans Affairs. The project is scheduled to recruit 4,700 veterans with cirrhosis from 47 VA medical centers. Cirrhosis is a major risk factor for liver cancer and affects veterans disproportionally.